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A Commentary on
Precision Immunotherapy for Sepsis
by Peters van Ton, A. M., Kox, M., Abdo, W. F., and Pickkers, P. (2018). Front. Immunol. 9:1926.
doi: 10.3389/fimmu.2018.01926
We read with interest the review article published in Frontiers in Immunology by Peters van Ton
et al., who suggest that precision immunotherapy might benefit organ failure and reduce the
mortality of sepsis patients. Sepsis is still an enormous health-threat worldwide and mortality rates
are still very high despite recent advances in early recognition. In that sense, we agree with Peters
van Ton and colleagues, a therapy that will reduce mortality and morbidity in sepsis patients is
urgently needed. The question is; will that be immunotherapy?
More than a century ago bacterial infection was recognized as the cause of sepsis. When
antibiotics did not save all patients, the logical step was to suspect a failing immune system. The
immune system is clearly an early and active responder during organ failure in sepsis but there
is more to the host response than just a derailed immune system. What clinical evidence really
supports the immune system as the key “organ” causing death in sepsis patients?
As the authors state, decades of failed clinical trials focusing on immunomodulating therapies
have not resulted in a new therapy for sepsis. Back in 1996, Roger Bone discussed the first failed
clinical trials and already suggested then, that the model of persistent, uncontrolled inflammation
was inaccurate (1). He pleaded that we should learn from our mistakes and emphasized the
necessity to examine all of the physiological responses the body was capable of mounting, not
simply the most or least severe (1). Instead, his advice was largely ignored, and a further 25 years
of clinical trials targeting the hyperinflammatory response in sepsis patients ensued; primarily
driven by the hope of finding the “magic bullet,” but also fueled by the pharmaceutical industry.
At that time, Bone mentioned that the anti-inflammatory response had, for the most part, been
ignored. However, in recent years it has gained increasing attention mainly due to the many
clinical trials that were unable to improve patient outcome. Sepsis induced-“immunosuppression”
or “immunoparalysis” is now thought to be one of the main drivers of mortality and morbidity in
patients, which has led to the birth of immunostimulatory compounds as a potential new therapy.
However, we fear that switching from taming an overactive immune system to stimulating
a depressed system, or even regulating the immune system on-demand will end up in new
disappointments. Moreover, recent evidence suggests that it’s not either-or, patients can become
hyperinflammed and immunosuppressed concurrently (2), questioning the usefulness and safety
of immunostimulatory compounds. We therefore agree with the authors, identifying patients that
might benefit from immunostimulatory compounds and those that might not is extremely crucial.
Many believe that patients succumb to sepsis as a result of secondary infection due to
immunosuppression and the inability to fight infection. Although this might be the case for some
patients, it certainly doesn’t hold true for all patients with sepsis. Van Vught et al., showed in their
study that only 13.5% of all sepsis ICU-admissions developed secondary ICU-acquired infection.
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Despite these patients having a higher disease severity score at
admission the contribution of secondary infection on overall
mortality was low (3). The authors also refer to studies showing
that pre-exposure to bacterial products resulted in improved
clearance and survival upon rechallenge with live bacteria (4, 5).
Moreover, a causal relationship between immune suppression
andmortality from ICU-acquired secondary infection has not yet
been reported.
The authors also highlight an important concept, it is
currently unknown whether the immune status of organs in
septic patients is comparable to the immune status within the
blood compartment. This knowledge is clinically important,
since as the authors state, tissue resident macrophages and
other cells appear to be primarily responsible for the innate
immune response in sepsis rather than the circulating immune
cells. Whether treatment with immunostimulatory compounds
results in further organ dysfunction is also currently unknown.
One might imagine that treatment with immunostimulatory
compounds that promote systemic TNFα release within the
blood compartment of immunosuppressed patients may be
beneficial if they need to fight secondary infection (6, 7), but
it may also result in detrimental cellular responses resulting in
further organ function deterioration.
Expecting immunotherapy to diminish organ failure in all
patients with sepsis is unrealistic. Recent studies have identified
sepsis endotypes with different clinical and molecular profiles
(8, 9). The host-response to sepsis therefore differs per patient
implying the need for different treatment strategies rather than
the traditional “one-size-fits-all” approach. These types of studies
should be embraced since this will unquestionably promote
recognition of specific groups for precise therapy as well as
advancing better clinical trial design.
There is also a danger that the immunotherapy hype will
overshadow investment into other promising therapies targeting
other aspects of organ failure. This would be unfortunate since
some patients will benefit from immunotherapy whereas others
may benefit from a different type of treatment, or more likely,
a combination of different therapies. In that sense, we really
have to broaden our view and support translational research
aimed at further elucidating the other “host-responses” and
mechanisms that may be mediating organ failure in patients
with sepsis, in order to uncover treatment strategies other than
immunotherapy.
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